A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. - Wikidata - awgldk - TriplyDB

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

http://www.wikidata.org/entity/Q37670967

about

Systematic review of dasatinib in chronic myeloid leukemia Harnessing the apoptotic programs in cancer stem-like cells Targeting BCL2-Proteins for the Treatment of Solid Tumours Concise review: Leukemia stem cells in personalized medicine Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche.Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model.The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.Novel targeted therapies for eosinophil-associated diseases and allergy Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer An RNA editing fingerprint of cancer stem cell reprogramming.Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma Capillary Isoelectric Focusing Immunoassay for Fat Cell Differentiation Proteomics.Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma.Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation.Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.Genetic events other than BCR-ABL1.Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment.Cancer stem cells: are they responsible for treatment failure?Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.Minimal Residual Disease Eradication in CML: Does It Really Matter?The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl-1.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics

P2860

Q24596026-0C76E26F-FEE9-43B9-8189-E968AFEE3803 Q26801037-4B80EBFC-A1C6-4CE1-9995-A4187816E8CA Q26853686-6941B097-195A-498D-B967-010A14575ECC Q26995268-B893B824-9AB0-4E0C-BDBB-FB06AD0A3F41 Q27324269-96059F8A-25F9-4163-8F5D-6E0A55956B26 Q28084243-82F710D7-E5D5-4710-9FBB-408F493E8ED6 Q28396457-12A2FA5D-CA23-41B6-AE44-B3D0FAFA9E10 Q28540799-946B4373-2051-40F8-A10C-15E9E063DA12 Q30457748-C7658F53-2156-44A8-9980-0C4F2A3EA6BD Q33418324-319105AF-795C-4E2E-B72D-A841EAC2F817 Q34117463-D89B803C-18C4-4FDC-B42B-A57527CFD6B6 Q34444620-DCF245DC-EB2F-4D93-A22E-8A1FD719B246 Q34486401-EC112CCF-DBFA-4A64-B744-636946BE5C5A Q35124728-15036E84-139A-4589-AB61-EC0CCE6B8F50 Q35579430-45483A99-B467-49CC-A9C1-FCC92F4C5548 Q35635358-861083BD-1AA1-43D8-9D63-A83618E2DE9B Q35679898-7FA6F135-6B06-4840-87AD-9BE624DBA9A4 Q35859229-8B61680F-1D64-4E16-9C23-82B535B3AFD1 Q35931271-F8D0B875-B5B7-4D2C-A8AF-63B83F3BF58E Q36140893-EA26709B-B554-4CDD-AD69-F70842EDACAA Q36394240-DD92B63D-13C7-4B22-93EB-CC6101E5E40A Q36544358-9D5CB323-5AA7-4C4E-A154-EE68935FA27F Q37273208-20E1B880-F373-4A1A-944F-DC5B82A4CCB0 Q37395704-9183DF28-50D6-4444-839B-05094536B186 Q37416797-B9084727-C7ED-41E0-B21A-7AA26F2EC5A0 Q37576728-FB37166A-334A-4ABB-94BA-B74D7AD240B4 Q38128358-7722FB00-9799-4E64-BDD2-2B4375D99820 Q38164593-57621B20-7DAF-476E-80B2-7C4520BD36C9 Q38175466-931A703E-F262-4433-BF9E-67DABCC3F85C Q38177162-919A347F-E926-4979-9081-4FEDA96FC6EA Q38206835-6E6D1F77-7FD0-41B8-9C57-271C764FD56E Q38268164-5FC2F8B6-A717-464D-AF64-C8794536F242 Q38322466-99A0A815-46A8-4A31-80AA-6FF17979EB56 Q38602633-2BDB1F94-9AE8-466D-AB73-44E86449946B Q38645695-D0BF4DA7-10A4-4D97-B631-DCECB3FE4446 Q38694287-EBE16302-64B4-433C-BC91-62366036CE94 Q38845834-FCD62A89-3639-4DE4-981A-47E22503DD5D Q38846360-98B5B408-F1CE-4236-9BD8-8A777F50D16B Q38866390-748E96B5-D5F6-4DF5-B304-513DD7D50507 Q38957684-8DCEB284-29F4-4654-8732-87A84F17B152

P2860

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

http://www.wikidata.org/entity/Q37670967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@en

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@nl

type

label

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@en

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@nl

prefLabel

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@en

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@nl

P1433

Q37670967-290AFB8D-0B27-46BB-8B6E-151B81006FC4

P1476

Q37670967-25906837-7F90-48FB-928D-83C67517AC4D

P2093

Q37670967-06DF18A1-EB07-4197-B944-4E5F2E11DEE4

Q37670967-0CF9E13A-5C61-42ED-B934-7B4BA9E9F7AF

Q37670967-0E69EC47-36D6-4944-AB3D-D363FD759E70

Q37670967-0F6FB1D7-9B2F-4A06-866C-46E5FE3D798A

Q37670967-135E436C-6929-41D3-AF18-85A4A4DDEB36

Q37670967-1E9AE200-599A-4588-ADD3-71C806225861

Q37670967-2012955D-4C6B-4E60-98F4-03241AE0EBDD

Q37670967-2D996373-219A-42AA-9A43-AC13DB7EBF0D

Q37670967-39BE69CE-07E5-4819-BB6E-800F22279F9D

Q37670967-3AF44156-67E6-46EE-9512-5EB975AD514C

P2860

Q37670967-0351FE6B-37CE-4D38-B136-04EACEF9932E

Q37670967-059B8547-796C-4AFB-8F3A-8D3F35BBB819

Q37670967-08D9D858-B4AB-4F16-B1ED-598C808371E2

Q37670967-1F8D399A-CEDA-4FC2-A212-FEF3BD8E5C61

Q37670967-2295C61D-1F80-4C24-89CB-D950E98B1A47

Q37670967-24588E85-D9F1-4981-8FA9-85F8608BA85D

Q37670967-26434A91-6EB1-4790-B242-26B8DE6E5DBD

Q37670967-28643F65-E06F-48B8-AC0C-BCE553EC40F5

Q37670967-2FD254DA-1312-4AC1-BBEE-DF9DFB51C2F8

Q37670967-303E3CD6-098D-4F39-8E78-A5253DDDFDA0

P304

Q37670967-73BF799A-9FB0-4A72-ABD5-2B80FD599F47

P31

Q37670967-07C55CDA-032A-4D6B-B738-3D892345F7DB

P356

Q37670967-5343AEA4-B267-4CE6-8C52-94CA9269F579

P407

Q37670967-569C4AF9-61F3-4D12-A6F8-DC0BE7D469EC

P433

Q37670967-BF058D47-C09D-418D-806F-46D8591A6876

P478

Q37670967-6AAFCBDA-F1E2-4572-BACB-0CD312A0C023

P50

Q37670967-8C2D76BF-60E0-42BD-9767-ACD273E0FAA4

Q37670967-F7C0D7DB-D629-42E6-A375-DD155DF08BE3

P577

Q37670967-54F82E6D-45C1-42E3-BE7B-2FA575EB470F

P5875

Q37670967-3D99C191-1501-4E53-9ECB-E4F74D477BBC

P698

Q37670967-D35D4A1A-B1AE-473A-AB30-22C83C81A6F9

P921

Q37670967-8AF3C3D8-8470-43EB-A455-807E2BEC5664

P932

Q37670967-0650A52B-0529-4F32-9EE0-912A109B4093

P356

J.STEM.2012.12.011

P1433

P1476

A Pan-BCL2 inhibitor renders b ...... to tyrosine kinase inhibition.

@en

P2093

Alice Y Shih

http://www.w3.org/2001/XMLSchema#string

Angela Court Recart

http://www.w3.org/2001/XMLSchema#string

Anil Sadarangani

http://www.w3.org/2001/XMLSchema#string

Catriona H M Jamieson

http://www.w3.org/2001/XMLSchema#string

Christian L Barrett

http://www.w3.org/2001/XMLSchema#string

Christina A M Jamieson

http://www.w3.org/2001/XMLSchema#string

Daniel J Goff

http://www.w3.org/2001/XMLSchema#string

Dayong Zhai

http://www.w3.org/2001/XMLSchema#string

Heather Leu

http://www.w3.org/2001/XMLSchema#string

Hye-Jung Chun

http://www.w3.org/2001/XMLSchema#string

P2860

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

Metastasis: a question of life or death

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Frequent pathway mutations of splicing machinery in myelodysplasia

Cells of origin in cancer

Are standardized mortality ratios valid for public health data analysis?

P304

316-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STEM.2012.12.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Thomas J. Hudson

Giovanni Martinelli

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234699306

http://www.w3.org/2001/XMLSchema#string

P698

23333150

http://www.w3.org/2001/XMLSchema#string

P921

P932

3968867

http://www.w3.org/2001/XMLSchema#string